

References

- **AASLD (American Association for the Study of Liver Diseases), (2000):** Update on viral hepatitis. Postgraduate Course. <https://www.aasld.org>.
- **Abdel-Aziz F, Habib M, Mohamed MK, et al. (2000):** Hepatitis C virus infection in a community in the Nile Delta. *Hepatology*, 32:111-115.
- **Adinolfi LE, Gambardella M, Andreana A, et al. (2001):** Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology*; 33:1358–1364.
- **Adinolfi LE, Ingrosso D, Cesaro G, et al. (2005):** hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. *Hepatology*; 41:995-1003.
- **Afdhal NH, Dieterich DT, Pockros PJ, et al.(2004):** Epoetin alfa maintains ribavirin dose in HCVinfected patients: a prospective, double-blind, randomized controlledstudy. *Gastroenterology* 2004;126:1302-1311
- **Akiko Yamane, Takanori Nakamura and Hidenori Suzuki (2008)** Interferon-2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes *Blood* :112. 542-550.
- **Akuta N, Suzuki F, Sezaki H, et al.,(2006):** Predictive factors of virologic-response to interferon-ribavirin combination therapy for

- patients infected with hepatitis C virus of genotype 1b and high viral load. *Journal of medical virology* 78:83-90
- **Alan Franciscus,(2011):** HCV Treatment:Predictors of Treatment Response HCSP • VERSION 5 • January 2011.
 - **Alberti A. (2005):** Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. *J. Hepatol.* 2005; 42: 266-274.
 - **Alberti, A. and Bersvegnu, L. (2003):** Management of hepatitis C. *Journal of Hepatology*; 38: S104-S118.
 - **Alberti, A.; Chemello, L. and Bonetti, P.(1993):**Therapy of acute hepatitis C. *Hepatology*; 36 (5 Suppl.1); S195-S200.
 - **Alfaleh FZ, Hadad Q, Khuroo MS, et al. (2004):** Peginterferon alpha-2b plus 40. ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int*; 24(6):568-74.
 - **Alter MJ (2006):** The epidemiology of viral hepatitis and HIV co infection. *Journal of hepatology* ;44:56-59
 - **Antonelli A, Ferri C, Pampana A, et al., (2004) :** Thyroid disorders in chronic hepatitis C.*Am J Med.*; 117(1):10-3.
 - **Armstrong GL , Walsey A , simard EP et al.,(2006):** The prevalance of hepatitis C virus infection in USA .*Ann of Intern med*; 144:705-714.
 - **Arora S, O'Brien C, Zeuzem S. (2006):** Treatment of chronic hepatitis C patients with persistently normal alanine

aminotransferase levels with the combination of peginterferon alpha- 2a (40 kDa) plus ribavirin: impact on health-related quality of life. *J Gastroenterol Hepatol*; 21: 406-412.

- **Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, et al.(2000):** Detection of hepatitis C virus replication by In situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. *Hepatology* 2000 Jul; 32(1): 97-103
- **Asselah T., Rubbia-Brandt L., Marcellin P., et al., (2006):** Steatosis in chronic hepatitis C: why does it really matter? *Gut*. 2006; 55(1):123-30.
- **Attili, A.F.; Rusticali, A. and Varriale, M. (1994):** The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial.
- **Bacht, E.A: Aguet, M. and Schreiber, R.D.(1997):** The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annu. Rev. Immunol.*,15:563-591.
- **Bacht, E.A: Aguet, M. and Schreiber, R.D.(1997):** The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annu. Rev. Immunol.*,15:563-591.
- **Bacon BR and Shiffman ML. (2009):** Phase 2 randomized, double-blind, placebo- controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: Interim analysis shows increase in EVR. *J Hepatol*; 50S: 381.

- **Bacon, B.R.(2002):** Treatment of patients with hepatitis with hepatitis C and normal serum aminotransferase levels. *Hepatology*; 36(5 Suppl.1):S179-S184.
- **Baglioni, C: Maroney, P.A. AND West,D.K.(1979).** 1,5 oligo (A) polymerase activity and inhibition of viral RNA synthesis in interferon treated Hela cells. *Biochemistry*, 18:1765-1770.
- **Bailon, p.: Schafer, C.A. and Spence, C. (1996):** Long lasting forms of poly ethylene glycol conjugated interferon- α 2a. Roche Research Report N-130915,May 3,1996.
- **Bartenschlager, R. and V. Lohmann (2000):** Replication of HCV. *J. Gen. virol* 81: 1631 – 1648.
- **Bass, B.L.(1997):** RNA editing and hypermutation by adenosine deamination. *Trends Bio. Chem. Sci.*, 22:157-162.
- **Batts KP, Ludwig J. (1995):** Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol* 1995; 19: 1409-1417
- **Bedossa P, Dargere D, Paradis V.(2003):** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003;38:1449-1457.
- **Bedossa P, Poynard T. (1996):** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; 24:289-293
- **Benhamou Y, Afdhal NH, Nelson DR. (2009):** A Phase III study of the safety and efficacy of viremagine versus ribavirin in treatment-naïve Patients with chronic hepatitis C: ViSER1 Results *Hepatology*; 50:717-726.

- **Benhamou Y, Di Martino V, Bochet M. (2001):** Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. *Hepatology*; 34: 283-287.
- **Bennett CL, Silver SM, Djulbegovic B, et al. (2008):** Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *Jama* 2008;299:914-924.
- **Berg T, Sarrazin C, Herrmann E. (2003):** Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology*; 37(3): 600-609.
- **Berg T, von Wagner M, Nasser S, et al (2008):** Tailored Treatment for Hepatitis C. *Clin Liver Dis* 2008;12:507–528.
- **Biasin, C.A. and Sen, G.C.(2001):** Interferons and other cytokines p. In D.M Knipe, p.m. Howley, D.E Griffin, M. Martin, B. Roziman and S.E. Strans (ed.), *Fields Virology*, 4th ed. Lippincott-Raven, Philadelphia, Pa. 321-351.
- **Biasin, C.A. and Sen, G.C.(2001):** Interferons and other cytokines p. In D.M Knipe, p.m. Howley, D.E Griffin, M. Martin, B. Roziman and S.E. Strans (ed.), *Fields Virology*, 4th ed. Lippincott-Raven, Philadelphia, Pa. 321-351.
- **Blair, R. C. (1981).** "A reaction to 'Consequences of failure to meet assumptions underlying the fixed effects analysis of variance and covariance.'" *Review of Educational Research*, 51, 499-507.

- **Boehm, U.; Klamp, T.; Groot, M. and Howard, J.G. (1997):** Cellular responses to interferon gamma. *Annu. Rev. Immunol.*, 15:749-795.
- **Bonacini M and Puoti M (2000):** Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. *Arch Intern Med* ;160(22):3365-73.
- **Booth J ,O’Grady J and Neuberger J (2001):**Clinical guidelines of the management of hepatitis C .*Gut.* ;49 (Suppl I):1-21
- **Booth, J.C.L.; O’Grady, J. and Neuberger, J.(2001):** Clinical guidelines on the management of hepatitis C. *Gut*; 49(Suppl. I): 11-121.
- **Bordin G, Ballaré M, Zignossi P(1995):** A laboratory and
- **Borrow P, Wei X, Howitz MS, et al., (1997):** Antiviral pressure exerted by HIV-1 specific CTLs during primary infection demonstrated by rapid selection of CTL escape virus *Nat. Med.*, 3:212-217.
- **Brau N, Bini EJ, Currie S et al. (2006):** Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. *J Viral Hepat*;13:242–249.
- **Bravo AA, Sheth SG, Chopra S. (2001) :** Liver biopsy. *N Engl J Med*; 344:495-500

- **Bressler BL, Guindi M, Tomlinson G et al. (2003):** High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology*; 38:639–644.
- **Brian L. Bressler,1 Maha Guindi,2 George Tomlinson,3 and Jenny Heathcote1** High Body Mass Index Is an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C:- *HEPATOLOGY* 2003;38:639-644.
- **Bruchfeld A, Lindahl K, Reichard O. (2006):** Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. *J Viral Hepat*; 13:316-321.
- **Bruchfeld A, Lindahl K, Schvarcz R. (2002):** Dosage of ribavirin in patient with hepatitis C should be based on renal function: a population pharmacokinetic analysis. *Ther Drug Monit*; 24: 701–708.
- **Bruno R, Sacchi P, Ciappina V, et al.(2004):** Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized,controlled study. *Antiviral Ther* 2004; 9(4): 491-497.
- **Bruno R, Sacchi P, Maiocchi L, et al.(2005):** Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. *Antiviral Ther* 2005; 10(2): 201-205.
- **Buti M, Sanchez-Avila F, Lurie Y, et al.(2002):** Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. *Hepatology*;35:930-936.

- **Calleri G, Cariti G, Gaiottino F. (2007):** A short course of pegylated interferon-alpha in acute HCV hepatitis. *J Viral Hepat*; 14:116-121.
- **Camma C, Bruno S, Di Marco V et al.,(2006):** Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006 43(1):64-71.
- **Carey WD, 2003:** Tests and screening strategies for the diagnosis of hepatitis C. *Cleveland Clinic Journal*; 70:7-13.
- **Carlsson T, Reichard O, Norkrans G, et al (2005):** Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. *J Viral Hepatol* 2005; 12:473-480.
- **Castera L, Vergniol J, Foucher J, LeBail B, et al.(2005):** Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005;128:343-350.
- **Castera L., Foucher J., Bertet J., Couzigou P., et al. (2006):** FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. *Hepatology* 2006; 43: 373-374.
- **Causse, X.; Godinot, H. and Chevallier, M. (1999):** Comparison of 1 or 3 Mu of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. *gastroenterology*; 111: 497-502.
- **Causse, X.; Godinot, H. and Chevallier, M. (1999):** Comparison of 1 or 3 Mu of interferon alfa-2b and placebo in

patients with chronic non-A, non-B hepatitis. gastroenterology; 101: 497-502.

- ***Centers for Disease Control and prevention. (2008):*** Hepatitis B virus. Frequently asked question, division of viral hepatitis for health professionals. July 21, 2008.
- ***Chang KM, Rehermann B, McHutcheon, et al., (1997):*** Immunological significance of CTL epitope variants in patients chronically infected with HCV. J. Clin. Invest., 100: 2376-2385.
- ***Chen, M.; Sonnerborg, A. and Sallberg, M. (1995):*** Levels of HCV RNA in serum and their relationship to level of immunoglobulin M and G antibodies against HCV core protein. J. Clin. Microbiol. 33,778–780.
- ***Cheng, S.J.; Bonis, P.A.L.; Lau, J.; Pharm, N.Q. and Wong, J.B.(2001):*** Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a metaanalysis of controlled and uncontrolled trials. Hepatology; 33:231-240.
- ***Cheruvattath R, Rosati MJ, Gautam M. (2007):*** Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci; 52:732-736.
- ***Chevaliez S and Pawlotsky JM.(2007):*** Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59:1222–1241.
- ***Choo QL, Kuo G, Ralston R, et al. (1994):*** Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. Usa; 91:1294-8.

- **Choo, Q.L.; G. Kuo; A.J. Weiner; L. R. Overby; M. Houghton (1989):** Isolation of a cDNA Clone derived from a blood- borne non- A, non- B viral hepatitis genome. *Science* 244: 359 – 362.
- **Choo, Q.L.; K. H. Richman; J.H. Han; K. Berger et al. (1991):**Genetic organization and diversity of the HCV. *Proc. Natl. Acad. Sci. USA.* 88: 2451–2455.
- **Chu CJ and Lee SD. (2008):**Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment (review). *Journal of Gastroenterology and Hepatology*;23:512–520.
- **Chung RT, Andersen J, Volberding P. (2004):** Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med*; 351: 451-459.
- **Colin C, Lanoir D, Touzet S, et al.(2001):** Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepatol* 2001; 8:87-95.
- **Colletta C., Smirne C., Fabris C., Toniutto P., et al. (2005):** Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. *Hepatology* 2005; 42: 838-845.
- **Conjeevaram HS, Fried MW, Jeffers LJ, et al.(2006):** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology* 2006; 131:470–477.

- **Conjeevaram HS, Kleiner DE, Everhart JE, et al. (2007):** Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology*; 45:80–87.
- **Corey KE, Ross AS, Wurcel A. (2006):** Outcomes and treatment of acute hepatitis C virus infection in a United States population. *Clin Gastroenterol Hepatol*; 4(10): 1278–1282.
- **Cornberg M, Hadem J, Herrmann E, et al. (2006):** Treatment with daily consensus interferon (CIFN) plus ribavirin in nonresponder patients with chronic hepatitis C: a randomized open label pilot study. *J Hepatology*; 44: 291-301.
- **Crawford DH, Roberts S, Weltman M, et al.(2008):** Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: the CHARIOT study. 43rd Annual Meeting of the European Association for the Study of the Liver 2008; 23-27.
- **Crockett SD and Keefe EB. (2005):** Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. *Ann Clin Microbiol Antimicrob*; 4:13-25
- **Crotty S, Cameron CE, Andino R.(2001):** RNA virus error catastrophe: direct molecular test by using ribavirin. *Proc Natl Acad Sci USA* 2001; 98:6895–6900.
- **Dal Molin, G.; D' Agaro, P.; Ansaldi, F., et al., (2002)-a:** Mother- to- infant transmission of HCV. Rate of infection and assessment of viral load and IgM anti – HCV as risk Factors. *J Med. Virol.* 67: 137 -142.

- **Dalgard O, Bjoro K, Ring-Larsen H, et al. (2008):** Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology*; 47:35–42.
- **Darling J.M.; Fried M.W. (2009):** Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. *Gastroenterology* 2009; 136(3):760-3.
- **Darnell, J.E.Jr.(1997):** STATs and gene regulation. *Science*, 277:1630-1635.
- **Darnell, J.E.Jr.; Kerr, I.M. and Stark, G.M.(1994):** Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science*, 264:1415-1421.
- **Datta SD, Armstrong GL, Roome AJ et al., (2003):** Blood exposure and hepatitis C virus infections among emergency groups. *Arch intern med*; 163:2605-2610.
- **David Breen, Scott Bryson, Catherine Chiang, et al. Scottish Executive.** Hepatitis C: proposed action plan in Scotland. Edinburgh: Scottish Executive; Blackwell's Bookshop 2005..
- **Davies PS, Day JM, Cole TJ(1993).:** Converting Tanner-Whitehouse reference tricep and subscapular skinfold measurements to standard deviation scores. *Eur J Clin Nutr.* 1993 Aug;47(8):559-66.
- **Davis GL, Wong JB, McHutchison JG, et al. (2003):** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38:645–652.

- **Davis GL. (2006):** new therapies: oral inhibitors and immune modulators. Clin Liver Dis; 10:865-880.
- **Davis, G.L.(2002):** Monitoring of viral levels during therapy of hepatitis C. Hepatology; 36((5 Suppl. 1);S145-51
- **De Franceschi L, Fattovich G, Turrini F, et al.(2000) :** Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997–1004.
- **De Maria, N.; A. Colantonia; R. Idilman; L. Friedlender; J. Harig (2002):** Impaired response to high dose interferon treatment in African–Americans with chronic hepatitis C. Hepatogastroenterology 49: 788–792
- **De Veer MJ, Holko M, Frevel M, et al.(2001):** Functional classification of interferon-stimulated genes identified using microarrays. J. Leukocyte Biol 2001; 69:912–920.
- **Desmet V.J.; Roskams T. (2004):** Cirrhosis reversal: a duel between dogma and myth. J. Hepatol. 2004; 40(5):860-7.
- **Desmet VJ, Gerber M, Hoofnagle JH, et al. (1994):** Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology; 19:1513-1520.
- **Desmond CP, Roberts SK, Dudley F, et al. (2006):** Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat; 13:311–315.

- **Desser, L. and Rehberger, A. (1990):** Induction of tumor necrosis factor in human peripheral blood mononuclear cells by proteolytic enzymes. *Oncology*; 47:474-477.
- **Deuffic-Burban S, Poynard T, Sulkowski MS, et al. (2007):** Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J Viral Hepat.*; 14: 107-115
- **Dhalluin C, Ross A, Leuthold L-A, et al.(2005):** Structural and biophysical characterization of the 40 kDa PEG interferon- α 2a and its individual positional isomers. *Bioconjugate Chem* 2005; 16 (3): 504-517.
- **Di Bisceglie AM, Shiffman ML, Everson GT, et al. (2008):** Prolonged therapy of advanced chronic hepatitis C with low-dose peg-interferon. *N Engl J Med.*; 359: 2429-2441.
- **Di Bisceglie AM. (2006):** Hepatitis C. *Clinical Hepatology* 2006; 2:235-248.
- **Di Bisceglie AM. and Hoofnagle JH (2002):** Optimal therapy of hepatitis C. *Hepatology* 2002; 36, S121–S127.
- **DiBisceglie, A.M. and Hoofnagle, J.H.(2002):** Optimal therapy of hepatitis C. *Hepatology*; 36(5 Suppl. 1): S121-127.
- **Dienstag JL (2002):** The role of liver biopsy in chronic hepatitis C. *Hepatology*; 36(Suppl): S152-S160.
- **Distante S, Bjoro K, Hellum KB et al. (2002):** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver*; 22:269–275.

- **Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, et al. 2004)** .Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology*; 40:1426-1433.
- **Dixit NM, Layden-Almer JE, Layden TJ, et al.(2004):** Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature* 2004; 432:922–924.
- **Doss W ,Esmat G ,El-sayed M et al., (2008):** Egyptian national control Strategy for viral hepatitis. National committee for control of viral hepatitis .Agency national de recherche sur le SIDA(ANRS) 6-12.
- **Dries V., Odenthal M., Schirmacher P. (2001):** Liver biopsy in chronic hepatitis C. Histopathology, molecular diagnostic analysis, and implications for therapeutic management. *Pathology* 2001; 22(6): 362-8.
- **Dsheiko, G. (1997):** Side effects of alpha interferon in chronic hepatitis C. *Hepatology*; 26 (Supl. 1):12 S-21S.
- **EASL International Conference on Hepatitis C (1999):** Paris, 26-28 February 1999, Consensus Statement. *J. Hepatol.*, 30:957-61.
- **El Makhzangy H, Esmat G, SaidM, et al (2009):** Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4. *Journal of Medical Virology* 81:1576–1583.
- **El-Serag HB, Hampel H, Rabeneck L et al., (2002):** Extrahepatic manifestations of hepatitis C among United States male veterans.*Hepatology*.;36(6):1439-45.

- ***El-Zayadi AR. (2009):*** Hepatitis C comorbidities affecting the course and response to therapy: *World J Gastroenterol*; 28: 15(40): 4993-4999.
- ***Erol S, Ozkurt Z. (2009):*** Poor response to treatment with peg-INF containing regimens in Patient coinfectd with hepatitis B and hepatitis C virus: *Hepatitis Monthly*; 9(3): 224-228.
- ***European Medicines Agency(2008):*** Summary of product characteristics Pegasys ®[online]2008; Available from URL: <http://www.emea.eu.int>.
- ***Fagerland, M.W., and L. Sandvik.(2009).*** The Wilcoxon-Mann-Whitney test under scrutiny. *Statist. Med.* 28: 1487-1497.
- ***Farci P, Strazzera R, Alter HJ, et al. (2002):*** Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proc Natl Acad Sci USA*; 99:3081–3086.
- ***Fargion S, Fracanzani AL, Sampietro M, et al. (1997):*** Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol*; 9:497–503.
- ***Feld JJ, Nanda S, Huang Y, et al. (2007):*** Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. *Hepatology* 2007;46:1548–1563.
- ***Ferenci P, (2004):*** Predictors of response to therapy for chronic hepatitis C. *Semin Liver Dis.* Vol.,24:25-31
- ***Ferenci P, Fried MW, Shiffman ML, et al (2005):*** Predicting sustained virological responses in chronic hepatitis C patients

treated with peginterferon alfa-2a (40KD) / ribavirin. J Hepatol 2005; 43:453–471.

- **Ferenci P, Laferl H, Scherzer TM, et al. (2008):** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology [Epub ahead of print].
- **Ferrell L.D., Theise N.D., Scheuer P.J. (2002):** Acute and chronic viral hepatitis. Pathology of liver, 4th edn. London: Churchill Livingstone; pp 313-362.
- **Ferri C., Zignego A.L., Pileri S.A. (2002):** Cryoglobulins. J. Clin. Pathol. 2002; 55:4-13.
- **Fiorentino DF, Ziotnik A, Viera P et al., (1991):** IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 146:3444.
- **Fireman, M.; Indest, D.W.; Blackwell, A.; et al. (2005):** Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 40(Suppl 5):S286-91.
- **Fissell RB, Bragg-Gresham JL, Woods JD. (2004):** Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int; 65(6):2335.
- **Fleig WE, Krummenerl P, Lesske J. (2004):** Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidence based consensus conference of the German Society for Alimentary

Metabolic Disorders and in cooperation with the Hepatitis Competence Network. *Gastroenterol*; 42(8):703-4.

- **Forns X, Garcia-Retortillo M, Serrano T et al.(2003):** Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. *J Hepatol* 2003; 39: 389-396.
- **Fracanzani AL, Conte D, Fraquelli M, et al. (2001):** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* ; 33:647–651.
- **Frank C, Mohamed K, Strickland T, et al.(2000),** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000;355: 887–891.
- **Friebe, P. and R. Bartenschlager (2002):**Genetic analysis of sequences in the 3' nontranslated region of HCV that are important for RNA replication. *J. Virol.* 76: 5326 – 5338.
- **Fried MW, Hadziyannis SJ, Shiffman M, et al. (2008):** Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol*; 48 (Suppl.2):5A.
- **Fried MW, Shiffman M, Reddy KR, Smith C, et al.(2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347:975-982.
- **Fried, M.W.; Shiffman, M.L.; Readdy, R.; et al. (2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.*, 347:975-982.

- **Fried, M.W.; Shiffman, M.L.; Readdy, R.; et al. (2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.*, 347:975-982.
- **Fried, M.W.; Shiffman, M.L.; Readdy, R.; et al. (2002):** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.*, 347:975-982.
- **Gaeta GB, Precone DF, Felaco FM, et al.(2002) :** Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2002; 16:1633–1639
- **Gehrke SG, Stremmel W, Mathes I, et al. (2003):** Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. *J Mol Med*; 81:780–787.
- **Gerlach JT, Diepolder HM, Zachoval R. (2003):** Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology*; 125(1):80-8.
- **Germer J.J., Vandenameele J. N., Mitchell P.S., Harmsen W.S., et al. (2004):** Automated sample preparation for the Trugene HIV-1 genotyping kit using the MagNA pure LC instrument. *Diagn. Microbiol Infect. Dis.* 2004; 49:59–61.
- **Giannini and Bréchet (2003) ,** Hepatitis C virus biology; *Cell Death and Differentiation* 2003;10:S27 ± S38
- **Giannini E, Botta F, Borro P, Risso P, et al.(2003):** Platelet count/spleen diameter ratio: proposal and validation of a non-

invasive parameter to predict the presence of oesophageal varices in liver cirrhosis. *Gut* 2003; 52:1200-1205.

- **Giannini EG (2006)** Thrombocytopenia in chronic liver disease and pharmacologic treatment options. *Aliment Pharmacol Ther* 23:1055-1065.
- **Glue P, Rouzier-Panis R, Raffanel C, et al (2000):** Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin. Pharmacol. Ther* 2000; 68, 556–567.
- **Gordon, E et al, 1998**
- **Grace MJ, Cutler D(2004).** Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. *Antivir Chem Chemother* 15: 287-297, 2004.
- **H.S. Conjeevaram, M. W. Fried, L. J. Jeffers et al.,** “Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1,”*Gastroenterology*, vol. 131, no. 2, pp. 470–477, 2006.
- **Hadziyannis SJ, Sette H, Morgan TR, et al (2004):** Peginterferon alfa- 2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140:346–355.
- **Hasan F, Asker H, Al Khaldi J, et al. (2004):** Peginterferon alfa- 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroenterol*; 99:1733–1737.
- **Heathcote Jand Main J. (2005):** Treatment of Hepatitis C; *J ViralHepat.* ; 12(3):223-235.

- **HeIM, m.h. (1999):** The Jak-STAT Pathway: cytokine signaling from the receptor to the nucleus. *J.Receptor Signal transduction Res.*, 19:25-120.
- **Hellstrom, U.B.; Sylvon, S.P.E.; Decker, R.H. et al., (1993):** Immunoglobulin M reactivity towards the immunologically active region P 75 of the core prate in of HCV in chronic HCV infection *J. Med. Viral* 39: 325–332.
- ***Herrnstein, R. J.; Loveland, D. H.; Cable, C. (1976).*** "Natural concepts in pigeons". *Journal of Experimental Psychology: Animal Behavior Processes* 2: 285–302. doi:10.1037/0097-7403.2.4.285.
- ***Hickman IJ, Clouston AD, MacDonald GA, et al. (2002):*** Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. *Gut*; 51:89-94.
- ***Hinrichsen H, Benahmou Y, Wedemeyer H. (2004):*** HCV protease inhibitor-BILN 2061: can STAT-C drugs be designed that are equally effective across genotypes? *Gastroenterology*; 127:1347.
- ***Hofer H, Osterreicher C, Jessner W, et al. (2004):*** Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol*; 40:1018–1022.
- ***Hoofnagle J (2002):*** Course and outcomes of hepatitis C. *Hepatology*,2002;36:S21-S29.
- ***Hui JM, Kench J, Farrell GC, et al.(2002):*** Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* 2002; 17:873–881.

- **Hwang SJ, Luo JC, Chu CW, et al. (2001):** Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol*; 16:190–195.
- **Isaacs, B.L. and Lindenmann, J. (1957):** Virus interference. I. The interferon. *Proc. R. Soc. London Ser.* 147:258-267. Quoted from Liang and Hoofnagle (2000).
- **Isaacs, B.L. and Lindenmann, J. (1957):** Virus interference. I. The interferon. *Proc. R. Soc. London Ser.* 147:258-267. Quoted from Liang and Hoofnagle (2000).
- **Isaacs, B.L. and Lindenmann, J. (1957):** Virus interference. I. The interferon. *Proc. R. Soc. London Ser.* 147:258-267. Quoted from Liang and Hoofnagle (2000).
- **Ishak K, Baptista A, Bianchi L, et al. (1995):** Histologic grading and staging of chronic hepatitis. *J Hepatology*; 22: 696.699.
- **Jacos, B.L. and Langland, J.O.(1996):** When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. *Virology*, 125:496-501.
- **Jacobi C, Wenkel H, Jacobi A, Korn K, Cursiefen C, Kruse FE(2007):** Hepatitis C and ocular surface disease.*Am J Ophthalmol.*;144(5):705-711.
- **Jaeckel E, Cornberg M, Wedemeyer H. (2001):** Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*; 345:1452-1457.
- **Jensen DM, Morgan TR, Marcellin P, et al. (2006):** Early identification of HCV genotype 1 patients responding to 24 weeks

- peginterferon alpha-2a (40 kd)/ ribavirin therapy. *Hepatology*; 43:954–960.
- **Jonas MM. (2002):** Children with hepatitis C. *Hepatology*; 36:S173-S178.
 - **Jorquera F, Monte MJ, Guerra J, et al. (2005):** Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. *J Gastroenterol Hepatol*; 20:547–554.
 - **Kamal SM, El Kamary SS, Shardell MD, et al. (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*; 46: 1732-1740.
 - **Kamal SM. (2009):** Hepatitis C genotype 4 therapy: increasing options and improving outcomes. *Liver Int*; 29 Suppl 1:39-48.
 - **Kantzanou, M.; M. Lucas; E. Bornes; H. Komatsu et al., (2003):** Viral escape and T. cell exhaustion in hepatitis C virus infection analyzed using class I peptide tetramers. *Immunol .Lett.* 85: 165 -171.
 - **Karnsakul W, Alford MK, Schwarz KB. (2009):** Managing pediatric hepatitis C: current and emerging treatment options, *Therapeutics and Clinical Risk Management*; 5: 651–660.
 - **Karupiah, G.; Xie, Q.W.; Buller, R.M.; Nathan, C.; Duarte, C. and MacMickin, J.D. (1993):** Inhibition of viral replication by interferon gamma induced nitric, 26:1445-1448.

- **Kau A, Vermehren J and Sarrazin C (2008):** Treatment predictors of a sustained virologic response in hepatitis B and C. *Journal of Hepatology*;49 :634–651.
- **Keam SJ. and Cvetkovi´c RS.(2008):** Peginterferon- α -2a (40 kD) Plus Ribavirin, A Review of its Use in the Management of Chronic Hepatitis C Mono-Infection. *Drugs* 2008; 68(9):1273-1317.
- **Keefe, E.B. (2003):** Liver transplantation. Current status and novel approaches to liver replacement *Gastroenterology*; 120: 749.
- **Kessel A., Rosner I., Zuckerman E. (2000):** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J. Rheumatol* 2000; 27:610-2.
- **Khanna VJ, Shieh S, Benjamin J, et al.(2000):** Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. *Arch Dermatol* 2000 Jun; 136(6): 755-7
- **Khuroo MS, Khuroo MS and Dahab ST. (2004):** Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther*; 20:931–938.
- **Kidney disease: improving global outcomes (KDIGO). (2008):** *Kidney Int Suppl*: S1-S99.
- **Kim WR (2002):** The burden of hepatitis C in the United States. *Hepatology*; 36: S30-S34.

- **Kita H, Moriyama T, Kaneko T et al., (1995):** A helper T-cell antigen knockout mice: reexamination of GD1a immunolocalization.
- **Kleiner DE.(2005):** The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. *Semin Liver Dis.* 2005;25:52-64
- **Knodell RG, Ishak KG, Black WC, et al.(1981):**Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981;1:431-435
- **Kobayashi S, Takeda T, Enomoto M, et al (2007):** Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int* 2007; 27:186-191.
- **Koda M., Matunaga Y., Kawakami M., Kishimoto Y., et al. (2007):** FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology* 2007; 45: 297-306.
- **Kolykhalov, A.A.; Mihalik, K.; Feinstons,et al (2000):** HCV encoded enzymatic activities and conserved RNA elements in the 3 non translated region are essential for virus replication in vivo . *J. Virol* 74: 4046 – 2051.
- **Koshy, A.; J.P. Madda; P. Marcellin; M. Martinot (2002):** Treatment of hepatitis C virus genotype- 4 related cirrhosis. *J. Clin. Gastroenterol* 35: 82 -85.

- **Koziel MJ, Dudley D, Afdhal N, et al., (1993):** Hepatitis C virus (HCV)-specific cytotoxic T-lymphocyte recognize epitopes in the core and envelope proteins of HCV. *J. Virol* 7: 7522.
- **Kronenberger B, Welsch C, Forestier N. (2008):** Novel hepatitis C drugs in current trials. *Clin Liver Dis*; 12:529–550.
- **Kruskal and Wallis(1952).** Use of ranks in one-criterion variance analysis. *Journal of the American Statistical Association* 47 (260): 583–621, December 1952.
- **Kumar D, Farrell GC, Fung C, et al (2002):** Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. *Hepatology*; 36:1266- 1272.
- **Large MK, Kittlesen DJ and Hahn YS (1999):** Suppression of host immune response by the core protein of HCV: Possible implication of HCV persistence. *J. Immunol.*, Vol. 162:931-938.
- **Lau JY, Tam RC, Liang TJ., et al.(2002):** Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology* 2002; 35:1002–1009.
- **Lauer G And Walker B (2001):** Hepatitis C Virus Infection. *N Engl J Med*, 2001; 345, (1), 41-52.
- **Lavanchy D and McMahon B(2000):** Worldwide prevalence and prevention of hepatitis C. In: *Hepatitis C*, Liang TJ, Hoofnagle JH, eds. San Diego, Academic Press. 185-202.
- **Layden, J.E. and Layden, T.J.(2001):** How can mathematics help us understand HCV? *Gastroenterology*; 120:1546-1549.

- **Lechner F. et al.(2001):** Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med*; 191:1499–1512.
- **Lecube A, Hernandez C, Simo R, et al. (2007):** Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Am J Gastroenterol*;102:2189–2195.
- **Lee S and Abdo A.,(2003):** Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. *Journal of Antimicrobial Chemotherapy* 2003; 51,487–491.
- **Lee WM, Dienstag JL, Lindsay KL, et al. (2004):** Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. *Control Clin Trials*; 25: 472-492.
- **Lengyel, P.(1993):** Tumor suppressor genes: news about the interferon connection. *Proc. Natl. Acad. Sci. USA*,90:5895
- **Lesniewsk, R.; Okasinski, G.; Vansont, C. et al., (1995):** Antibody to HCV- E2 glycoprotein: a new marker of HCV infection closely associated with viraemia. *J. Med. Virol.* 45: 415–422.
- **Levey AS, Coresh J, Balk E. (2003):** National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med*; 139:137-147.
- **Lindahl K, Schvarcz R, Bruchfeld A, et al.(2004):** Evidence that plasma concentration rather than dose per kilogram body weight

predicts ribavirin-induced anaemia. J Viral Hepatol 2004; 11:84–87.

- **Lindahl K, Stahle L, Bruchfeld A, et al.(2005):** High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005;41:275-279.
- **Lindsay K, Manns MP, Gordon SC et al. (2008):** Clearance of HCV at 5 year follow-up for peginterferon alfa-2b with or without ribavirin is predicted by sustained virologic response at 24 weeks post-treatment. Gastroenterology; 134 (Suppl. 1):772A.
- **Lindsay KL, Treppe C, Heintges T, et al.(2001):** A randomized, doubleblind trial comparing PEGylated interferon alfa-2b to interferon α -2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395–403.
- **Lindsay, KL.(1997):** Therapy of hepatitis C; overview. Hepatology;26(Suppl.1):715-75.
- **Linng and Hoofnagle, 2000**
- **Lisker-Melman, M.; DiBisceglie, A.M.;Usla, S.J.;Weintraub, et al (1992):** Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology; 102:2155-60.
- **Liu C., Zhu H., Subramanian G.M., Moore P.A., et al. (2007):** Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol. Res. 2007; 37(11):941-7.
- **Lonardo A. , Loria P, Adinolfi L, et al.,(2006):** Hepatitis C and steatosis: a reappraisal. Journal of Viral Hepatitis 2006, 13, 73–80.

- **Ludewig B, Ehl S, Karrer U, et al., (1998):** Dendritic cells efficiently induce protective antiviral immunity. *J. virol.* 72:3812-18.
- **Lyra AC, Fan X and Di Bisceglie AM (2004):** Molecular biology and clinical implication of hepatitis C virus. *Brazilian Journal of Medical and Biological Research*; 37: 691-695.
- **Maheshwari A and Thuluvath PJ. (2010):** Management of Acute Hepatitis C. *ClinLiverDis*; 14:169–176.
- **Mangia A, Minerva N, Bacca D, et al. (2008):** Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. *Hepatology*; 47:43–50.
- **Mangia A, Santoro R, Minerva N, et al. (2005):** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med*; 352:2609–2617.
- **Mangia, A; Santoro, R; Pittelli, M; et al. (2002):** High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. *J. Hepatol*; 37(1):109-16
- **Manns MP, McHutchison JG, Gordon SC, Rustgi VK, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2a for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 2001;358:958-965.
- **Manns, M.P.; McHutchinson, J.C.; Gordon, S. et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet*; 358:958-965.

- **Manns, M.P.; Mchutchinson, J.C.; Gordon, S.et al.(2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomized trial. *Lancet*; 358;958-965.
- **Marcellin P, Lurie Y, Rodrigues Torres M. (2007):**The safety and efficacy of taribavirin plus pegylated interferon alfa 2a versus ribavirin plus pegylated interferon alfa 2a in therapy naïve patients infected with HCV: *Hepatology*; 46 (Suppl 1): S7.
- **Marie, I; Durbin, J.E. and Levy, D.E.(1998):** Differential viral induction of distinct interferon alpha genes by positive feedback through interferon regulatory factor 7. *EMBO J.* 17:6660-6669.
- **Martin LM, Younossi ZM, Price L, et al.(2001):** The impact of ribavirin induced anemia on health-related quality of life. *Hepatology* 2001; 34(suppl):600A. Abstract.
- **McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE.(2006):** Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.*Ann Intern Med.*;144(10):735-41.
- **McHutchinson et al., 1998**
- **McHutchinson, J.G.and poynard (1999):** The impact of race on response to anti-viral therapy in patients with chronic hepatitis C. *Hepatology*;30:302 A.
- **McHutchison J(2004).** Understanding Hepatitis C: *Am J Manag Care*.2004;10:S21-S29.

- **McHutchison JG, Dusheiko G, Shiffman ML, et al.(2007) :** Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007;357:2227-2236.
- **McHutchison JG, Poynard T, Pianko S, et al. (2000):** The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. *Gastroenterology*; 119:1317–1323.
- **McKee D.H., Young A.C., Alonso-Dominguez A., Tembl J.I., et al. (2000):** Neurologic complications associated with hepatitis C virus infection. *Neurology* 2000; 55: 459 - 459.
- **Mignogna MD, Lo Muzio L, Lo Russo L, et al.(2000):** Oral lichen planus: different clinical features in HCV-positive and HCV-negative patients. *Int J Dermatol* 2000 Feb; 39(2): 134-9.
- **Missale G, Bertoni R, Lamonaca V, et al., (1996):** Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J clin. Invest.* 98:706-714.
- **Missiha S, Heathcote J, Arenovich T et al. (2007):** Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol*; 102:2181-2188
- **Mohamed MK.** Epidemiology of HCV in Egypt 2004. *The Afro-Arab Liver Journal*, 2004, vol 3, No2, (July), pp 41-52
- **Mondelli M.(2003),** Natural history of hepatitis C virus infection. *Journal of Biological Regulators and Homeostatic Agents* 2003;17: 128-32.

- **Mondelli, M.U. and Sillini, E. (2000):** Clinical significance of HCV genotypes. *J. Hepatol.* 31: 65–70.
- **Mood, Alexander; Franklin A. Graybill, Duane C. Boes (1974).** Introduction to the Theory of Statistics (Third Edition, p. 241-246). McGraw-Hill.
- **Murphy, F.A.; C.M. Fraquet; D.H.L. Bishop; S.A. Ghabrial et al., (1995):** Classification and nomenclature of viruses: sixth report of the internal committee on taxonomy of viruses. *P.* 424 – 426.
- **Murray KF, Rodrigue JR, Gonzalez-Peralta RP. (2007):** Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. *Clin Trials*; 4:661-673.
- **Myers R.P., Ratziu V., Imbert-Bismut F., Poynard T., et al. (2002):** Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. *Am. J. Gastroenterol.* 97(9):2419-25.
- **Nafeh MA, Medhat A, Shehata M, et al (2000):** Hepatitis C in community in upper Egypt: I. Cross- sectional survey. *Am J Trop Med Hgy* 2000; 63:236-241.
- **Nagayoma R, Miyake K, Tsuda F, et al., (1994):** IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of the disease. *J. Virol.*,68: 4420
- **Nathan, C. (1997):** Inducible nitric oxide synthase; What difference does it make? *J. Clin. Invest.*, 100:2417-2423.
- **National Institutes of Health Consensus Development Confernece (2002):** Management of hepatitis C. *Gepatology*; 36(5 Suppl.1): S3-S13.

- **National Institutes of Health (NIH). (2002):** Consensus development program and the state-of-the-science conferences. Management of hepatitis C. Washington, DC: National Institutes of Health;1-46.
- **Ndjomou, J.; B. Kupfero; B. Kochan; L. et al (2002):** HCV infection and genotypes among human immunodeficiency virus, high risk groups in Cameroon. J. Med. Virol 66: 179 -186
- **Neumann, A.U.;Lam, N.P. and Dahrari, G. (1998):** Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon alpha therapy. Science; 282:103-7.
- **Ning, Q; Brown, D. and parodo, J.(1996):** Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves TH1 cytokine production but inhibits TH2 cytokine response. Hepatology; 24:355.
- **Novozhenov V, Zakharova N, Vinogradova E. (2007):** Phase II study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol; 46(3):631-9.
- **Nucci, M.L; Shorr, R. and Abuchowski, A.(1991);** The therapeutic value of polyethylene glycol modified proteins. Adv. Drug Delivery Rev., 6:133-151.
- **of HCV in bone marrow exhaustion? Clin Exp Rheumatol 13:39-43.**
- **Okafor O and Segun O, 2004:** A comparative analysis of six current histological classification schemes and scoring systems used in chronic hepatitis reporting. Rev Esp Patol; 37:269-277.

- **Orland JR, Wright TL, Cooper S. (2001):** Acute hepatitis C. *Hepatology*; 33: 321-327.
- **Orland, J.R.; Wright, T.L. and Cooper,S.(2001):** Acute hepatitis C. *Hepatology*; 33:321-327.
- **Ortiz V, Berenguer M, Rayon JM et al. (2002):** Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol*; 97:2408–2414.
- **Oxford, J.S. and Galbraith, A.(1980):** Antiviral activity of amantadine : a review of laboratory and clinical data. *Pharmacol. Ther.*, 11;181-262.
- **Palumbo E. (2009):** Treatment for Chronic Hepatitis C in Children: A Review *American Journal of Therapeutics*; 16: (5) 446-450.
- **Papo, T.; Marcellin, P.; Bernuau, J.; et al (1992):** Autoimmune chronic hepatitis exacerbated by alpha interferon. *Ann. Intern. Med.*, 116:51-3.
- **Pascu M, Martus P, Hohne M, et al. (2004):** Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut*; 53:1345–1351.
- **Patel K, Norris S, Lebeck L et al (2006):** HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. *Hepatology* 2006; 43(2):241–249.
- **Patterson, J.B. and Samuel, C.E.(1995)** Expression and regulation by interferon of a double stranded RNA specific

adenosific adenosine deaminase from human cells is inducible by alpha and gamma interferons . Virology, 210:508-511.

- **Patton, H.M.; Patel, K.; Behling, C.; et al. (2004):** The impact of steatosis on disease progression and early virological response in chronic hepatitis C patients. J. Hepatology 40 (3) 533 -535.
- **Pawlotsky JM (2002):** Molecular diagnosis of viral hepatitis. Gastroenterology; 122: 1554-1568.
- **Pawlotsky JM, Ben Yahia , et al., (2004):**Immunologic disorders in C virus chronic active hepatitis :A prospective case control study . Hepatology ;19:841
- **Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al., (1995):** Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 122:169-73.
- **Pearlman BL, Ehleben C and Saifee S. (2007):** Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology; 46:1688–1694.
- **Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al.(2002):** Rapid suppression of hematopoiesis by standard or pegylated interferon- alpha. Gastroenterology 2002; 123:141–151.
- **Penin F., Dubuisson J., Rey F.A., Moradpour D., et al. (2004):** Structural biology of hepatitis C virus. Hepatology. 2004; 39:5-19.
- **Perelson AS et al.(2005):** New kinetic models for the hepatitis C virus. Hepatology 2005; 42: 749–754.

- **Perry CM and Jarvis B.(2001):** Peginterferon- α -2a (40 kD), a review of its use in the management of chronic hepatitis C. *Drugs* 2001;61(15): 2263-2288.
- **Pileri, P.; Uematsu, Y.; Campagnoli, S. et al., (1998):** Binding of HCV to CD81. *Science*; 282: 938-941.
- **Pockros PJ, Shiffman ML, Schiff ER, et al.(2004) :** Epoetin alfa improves quality of life in anemic HCVinfected patients receiving combination therapy. *HEPATOLOGY* 2004;40: 1450-1458.
- **Pothoff A, Wedemeyer H, Boecher WO. (2008):** The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. *J Hepatol*; 49: 688-694.
- **Powell EE, Jonsson JR and Clouston AD, (2005):** Steatosis: co-factor in other liver diseases. *Hepatology*; 42:5-13.
- **Poynard T, Marcellin P, Lee SS, et al(1998):** Randomised trial of interferon-a2b plus ribavirin for 48 Weeks or for 24 Weeks versus interferon-a2b plus placebo for 48 Weeks for the treatment of chronic infection with hepatitis C virus. *Lancet* 1998;352:1425-32.
- **Poynard T, Marcellin P, Lee SS, et al(1998):** Randomised trial of interferon-a2b plus ribavirin for 48 Weeks or for 24 Weeks versus interferon-a2b plus placebo for 48 Weeks for the treatment of chronic infection with hepatitis C virus. *Lancet* 1998;352:1425-32.
- **Poynard T, McHutchison J, Goodman Z et al. (2000):** Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen

possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology*; 31:211–218.

- **Poynard T, Ratziu V, Charlotte F et al. (2001):** Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. *J Hepatol*; 34:730–739
- **Poynard T., Munteanu M., Ngo Y., Torres M., et al. (2006):** Diagnostic value of FibroTest with normal serum aminotransferases. *Hepatology* 2006; 43: 374-375.
- **Ptossi, F.; Blank, A.; Schreder, A.; Hussi, P. et al .(1993):** A functional GTP-binding motif is necessary for antiviral activity of MX proteins. *J. Virol.*, 67:6726-632.
- **Putoi M, Airoidi M, Bruno et al ., (2002):** Hepatitis B co – infection in human immuno -deficiency virus-infected subjects . *AIDS Rev*; 4:27-35.
- **Pybus, O.G.; M.A.Charleston; S.Gupta; et al (2001):** The epidemic behavior of HCV. *Science* 292: 2323-2325.
- **Raimondo G, Brunetto MR, Pontisso P. (2006):** Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. *Hepatology*; 43: 100–7.
- **Raison CL, Demetashvili M, Capuron L, et al.(2005):** Neuropsychiatric adverse effects of interferon-alpha: recognition and management. *CNS Drugs* 2005;19:105-123.
- **Ramos-Casals M, Mañá J, Nardi N, et al. (2005):** Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. *Medicine (Baltimore)*. ;84(2):69-80

- **Ray R, Khanna A, Legging ML, et al., (1994):** Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. *J. Hepatol.* 21 : 403-5
- **Ray SC, Arthur RR, Carella A, et al. (2000):** Genetic epidemiology of hepatitis 4. C virus throughout Egypt. *J Infect Dis*; 182(3):698-707.
- **Recanelli, V. and B. Rehermann (2003):**HCV infection: when silence is deception.*Trends Immunol* 24: 456-464.
- **Reddy KR, David RN, Zeuzem S, et al.(2009):** Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. *J Hepatol* 2009; 50:402–411.
- **Reesink HW, Zeuzem S, Weegink CJ. (2006):** Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology*; 131:997-1002.
- **Regev A, Berho M, Jeffers LJ. (2002):** Sampling error and intraobserver variation in liver biopsy in patients with chronicHCVinfection.*AmJ Gastroenterol*; 97:2614- 2618.
- **Reichard, O.; Giaumann, H.; Fryden, A.; et al (1999):** Long term follow up of chronic hepatitis C patients with sustained virological response to alpha interferon. *J.Hepatol.*, 30:783-7.
- **Reiser, M., C. Marousis, D. Nelson, G. et al. (1997):**Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. *J Hepatol.* 26(3):471-8.

- **Reiss Gand Keffe EB. (2005):** Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol Disord*; (5):195-205.
- **Renault PF, Hoofnagle JH(1989).** Side effects of alpha interferon. *Semin Liver Dis* 1989; 9:273-277.
- **Renault, P.F.; Hoofnagle, J.H. and park, Y. (1987):** Psychiatric complications of long term interferon alpha therapy. *Arch. Intern. Med.*, 147:1577-80.
- **Rigopoulou EI, Abbott WG, Williams R, et al.(2007):** Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. *Antiviral Res* 2007; 5:36–42.
- **Rijnbrond, R.C.A. and S.M. Lemon (2000):** Internal ribosome entry site- mediated translation in HCV replication, P.85-116. In C.Hagedorn and C.M. Rice (ed), *Hepatitis C virus*, vol. 242. Springer – Verlag, Berlin, Germany.
- **Robert I. Handin, MD, Brigham and Women's(2005) :** Hematology interferon therapy in hepatitis c virus
- **Roberts EA and Yeung L (2002):** Maternal –infant Transmission of hepatitis C virus infection. *Hepatology*; 36:106-113.
- **Rocha CM, Perez RM, Ferreira AP. (2006):** Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. *Liver Int*; 26:305-310.
- **Rockey DC and Bissell DM (2006):** Noninvasive measures of liver fibrosis. *Hepatology*; 43 (Suppl): S113-S120.

- **Ross AS, Bhan AK, Pascual M, et al., 2004:** Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. *Clin Transplant*; 18:166-173.
- **Rossi, S.J. and Wright, T.L.(2003):** New developments in the treatment of hepatitis C. *Gut*; 52: 756-757.
- **Rossignol J.F., Elfert A., El-Gohary Y., Keeffe E.B., et al. (2009):** Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology* 2009; 136(3):856-62.
- **S. Pionko; S.C. Gordon et al., (2000):** The impact of interferon plus ribavarin on response to therapy in black patients with chronic hepatitis C. The international hepatitis interventional therapy group. *Gastroentrology* 119: 1317 – 1323.
- **Sabry AA, Sobh MA, Sheaaashaa HA, et al.(2002)** Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. *Nephrol Dial Transplant.* ;17(11):1924-30.
- **Sagir A, Erhardt A, Schmitt M, et al. (2008):** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology*; 47: 592-595.
- **Sakr MA, Esmat G, Hamid WA, et al.(2006):** Effect of body mass index, diabetes mellitus and hepatic steatosis on response to peg-interferon therapy in chronic HCV patients genotype 4. *Ain shams faculty of medicine* 2006; 144- 153.
- **Salama MM, Gameel KA, El Shereafy MS et al. (2007):** Assessment of steatosis in chronic hepatis C patients responders & nonresponders to combined pegylated interferon and ribavarin

therapy. National liver institute, Menoufiya university 2007; 6: 80-90; 3: 40-43

- **Salmeron J, Casado J, Rueda PM, et al. (2008):** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. *J Clin Virol*; 41:264–269.
- **Sanchez-Tapias JM, Diago M, Escartin P, et al. (2006):** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology*; 131:451–460.
- **Sandrin L, Fourquet B, Hasquenoph JM, Yon S, et al.(2003):** Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003;29:1705-1713.
- **Sarrazin C, Gartner BC, Sizmann D, et al. (2006):** Comparison of conventional PCR with realtime PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. *J Clin Microbiol*; 44:729–737.
- **Schering Corporation (2006):** PEG-Intron (Peginterferon alfa-2b) powder for injection: US prescribing information [online] 2006; Available from URL: www.pegintron.com.
- **Schervish MJ (1996).** "P Values: What They Are and What They Are Not". *The American Statistician* 50 (3): 203–206.
- **Scheuer PJ.(1991):** Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol* 1991; 13:372-374
- **Schiff E, Michael F and Willis C (2007):** HepatitisC. Schiff'S disease of the liver .Gary D.Tenth Edition ,part 2.30;819-834.

- **Schinkel, J.; Spaan, W.J.; Kroes, A.C. (2004):** Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. *Antivir Ther*
- **Scott JD and Gretch DR.(2007);** Molecular diagnostics of hepatitis C virus infection: a systematic review. *Jama* 2007; 297:724-732.
- **Searle J, Leggett BA, Crawford DHG, et al.(2002):** . Iron storage diseases. In: MacSween RN, Burt AD, Portmann BC et al, eds. *Pathology of the Liver*, 4th ed. London, England: Churchill Livingstone; 2002:257-272
- **Sebastiani G.; Alberti A. (2006):** Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. *World J. Gastroenterol.* 2006; 12: 3682-3694.
- **Seeff LB, Miller RN, Rabkin CS. (2000):** 45Years follow-up of hepatitis C virus infection in healthy young adults. *Ann Intern Med* 2000; 132:105-11.
- **Seeff LB., (2005):** Natural history of hepatitis C. *Hepatology. Rev.* Vol.,2:88-96
- **Seigel CA, Silas AM, Suriawinata AA, Van Leeuwun DJ. (2005):** Liver biopsy: when and how? *Cleveland Clin J Med* 2005; 72:199-224.
- **Sharma RK, Bansal SB, Gupta A. (2006):**Chronic hepatitis C virus infection in renal transplant: treatment and outcome. *Clin Transplant*; 20:677-683.

- **Sheila Sherlock and James Dooley (2002):** Diseases of the liver and biliary system.
- **Shepard C.W., Finelli L., Alter M.J. (2005):** Global epidemiology of hepatitis c virus infection. *Lancet Infect. Dis.* 2005; 5:558-567.
- **Sherman KE, Rouster SD, Chung RT. (2002):** Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin Infect Dis*; 34: 831-837.
- **Sherman M, Yoshida E M, Deschenes M. (2006):** Peginterferon alfa α 2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. *Gut*; 55(11): 1631–1638.
- **Shiffman ML, Ghany MG, Morgan TR, et al(2007):** Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. *Gastroenterology* 2007;132:103-112.
- **Shiffman ML, SuterF, Bacon BR et al (2007):** Peg interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2007; 357:124–134.
- **Shiffman, M.L.(2002):** Retreatment of patients with chronic C. *Hepatology*; 36(5 Suppl.1):S128-34.
- **Shindo M, Arai K, Sokawa Y, et al., (1995):** The virological and histological states of anti-hepatitis C virus-positive subjects with normal. *Ann Intern Med.* 122:586-91.
- **Shintani Y, Fujie H, Miyoshi H, et al. (2004):** Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology*; 126:840–848.

- **Silva IS, Ferraz ML, Perez RM, et al. (2004):** Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol*; 19:314–318.
- **Silva M, Poo J, Wagner F, et al(2006):**A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). *J Hepatol* 45: 204-213, 2006.
- **Simmonds P, Bukh J, Combet C, Deléage G, et al.(2005):** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* 2005; 42:962-973.
- **Singer ME and Younossi ZM (2001):** Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. *Am J Med* 3: 614-621.
- **Smith, P.J.(1997):** Treatment of chronic hepatitis C with amantadine. *Digest. Dis. Sci.* vol. 42(8):1681-1687.
- **Soza A, Everhart JE, Ghany MG. (2002):**Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *Hepatology*; 36:1273-1279.
- **Soza A,everhartJ.E,Ghany M.G,etal(2002):** Neutropenia during combination herapyof interferon alfa and ribavirin for chronic hepatitis c.*Hepatology*,2002:36:1273-1279.
- **Sporea I, Danila M, Sirli R, et al.(2006):** Comparative Study Concerning the Efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in Patients with

- Chronic Viral C Hepatitis. *Gastrointest Liver Dis* 2006;15(2):125-130.
- **Staeheli, P.; Pitossi, F. and pavlovic, J. (1993):** MX proteins: GTPases with antiviral activity. *Trends Cell Biol.*, 3:268-272.
 - **Steckelberg J (2007):** Hepatitis C: How common is sexual transmission?. Mayo Clinic Staff, Nov. 17. [www. Mayo Clinic.com /health/AN0070](http://www.MayoClinic.com/health/AN0070).
 - **Strader D.B., Wright T., Thomas D.L., Seeff L.B. (2004):** Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases Practice Guideline. *Hepatology* 2004; 39:1147-1171.
 - **Sulkowski M, Shiffman ML, Afdhal NH et al.(2008):** Treatment-related anemia but not epoetin use (EPO) is associated with higher SVR rates among persons treated with peginterferon (PEG)/ribavirin (RBV): Results from the IDEAL Study. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco; Abstract 1851.
 - **Surnacco, G.; Rosina, and Abate, M.L. (1993):** Long term follow up of patients with chronic hepatitis C treated with different doses of interferon α . *Hepatology*; 18:1300-5.
 - **T., Halfon P., Castera L., Munteanu M., et al. (2007):** Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. *Clin. Chem.* 2007; 53(9):1615-22.

- **Takashi Himoto AND Mikio Nishioka (2008)** Autoantibodies in Hepatitis C Virus-Related Chronic Liver Disease, *Hepatitis* 8:295-303,
- **Tanaka ,Y.; Agha ,S.; Saudy , N .; et al (2004)** : Exponential spread of hepatitis C virus genotype 4 a in Egypt. *Journal of molecular science* .
- **Tangiguchi, T. (1988):** Regulation of cytokine gene expression. *Annu. Rev. Immunol.*, 6:436-464.
- **Tassopoulos NC. (1999):** Treatment of patients with chronic hepatitis C and normal ALT levels. *J Hepatol*; 31(1):193-6.
- **Teuber G, Pascu M, Berg T et al.(2003):** Andomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. *J Hepatol* 2003; 39: 606-613.
- **Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al., (2005):** Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol*; 17:149-153.
- **Thuluvath PJ, Krok KL, Segev DL. (2007):** Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. *Liver Transpl*; 13:719-724.
- **Torriani FJ, Rodriguez-Torres M, Rockstroh JK. (2004):** Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*; 351:438-450.

- **Tovey, M.G. (1988):** The expression cytokines in the organs of normal individuals, in homeostasis. *J.Biol.Rev. Hemostat. Agents* ,2:87-92
- **Vilcek, J. and DeMaeyer, E. (1984):** Interferons and immune system. Elsevier Science Publishers, Amsterdam.
- **Vo NV, Young KC, Lai MM.(2003):** Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. *Biochemistry* 2003; 42:10462–10471.
- **Von Wagner M, Huber M, Berg T. (2005):** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology*; 129(2):522-7.
- **Wakil A and Merezban Z (2006):** Hepatitis C in Egypt. In *Egypt today magazine*. .HCV adovacte ,2006.WWW. HCV adovacte.org.
- **Washington K., Wright K., Shyr Y., Hunter E.B., et al. (2000):** Hepatic Stellate Cell Activation in Nonalcoholic Steatohepatitis and Fatty Liver. *Hum. Pathol.* Jul; 31(7):822-8.
- **Watanabe, N. Enomoto, and N. Enomoto (2010):** “Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan,” *Hepatology Research*, vol. 40, no. 2, pp. 135–144, 2010.
- **Watt K, Veldt B, Charlton M. (2009):** A Practical guide to the management of HCV infection following liver transplantation. *American Journal of Transplantation*; 9: 1707–1713.

- **Wedemeyer, H.; X.S. He; M. Mascimben, et al (2002):** Impairment effector function of HCV- specific CD8+ T cells in chronic HCV infection. *J. Immunol.* 169: 3447-3458.
- **Weisner, R.H.; Sorrell, M.; and Willani, F. (2003):** Report of the first International Liver Transplantation Society Expert Panel Consensus Conference of Liver Transplantation.
- **Wells et al, 1985**
- **Wiegand J, Deterding K, Cornberg M. (2008):** Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon, *J Antimicrob. Chemother*; 62: 860 - 865.
- **Williams R (2006):** Global challenges in liver disease. *Hepatology*; 44: 521-526.
- **Wong JB(2006). Hepatitis C:** cost of illness and considerations for the economic evaluation of antiviral therapies. *Pharmacoeconomics* 2006; 24: 661-72
- **World Health Organization (2008):** Hepatitis B : Key facts. WHO mediacenter. August 2008 No 204:1-4.
<http://www.who.int/mediacentre/factsheets/fs204/en/> Accessed on August 2008.
- **Wright, T.L.(2002);** Treatment of patients with hepatitis C and cirrhosis. *Hepatology*; 36(5 Suppl.1):S185-S194.
- **Wright, T.L.(2002);** Treatment of patients with hepatitis C and cirrhosis. *Hepatology*; 36(5 Suppl.1):S185-S194.

- **Yano M, Kumada H, Kage M et al., (1996):** The long-term pathological evolution of chronic hepatitis C. *Hepatology*; 23:1334-1340.
- **Yi, M. and S.M. Lemon (2003):** 3' Nontranslated RNA signals required for replication of HCV RNA. *J. Virol* 77: 3557-3568.
- **Yu ML, Dai CY, Lee LP. (2006):** A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. *Liver Int*; 26:1187-1195.
- **Zein, N.N. (2000):** Clinical significance of HCV genotypes. *Clin. Microbiol.Rev.* 13: 223-235.
- **Zekri AR, Bahnassy AA, Ramadan AS et al.(2001):** . Hepatitis C virus genotyping versus serotyping in Egyptian patients. *Infection* 2001; 29: 24-26.
- **Zeuzem S (2008):** Interferon-based therapy for chronic hepatitis C: current and future perspectives. *nature clinical practice J Gastroenterol Hepatol* 2008; 5(11):610-622.
- **Zeuzem S, Buti M, Ferenci P. (2006):** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol*; 44(1): 97-103.
- **Zeuzem S, Diago M, Gane E et al.(2003):** Ontrolled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 kD) (Pegasys) and ribavirin (Copegus). *AASLD 2003* (abstract).

- **Zeuzem S, Diago M, Gane E. (2004):** peinterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology*; 127 (6): 1724 - 32.
- **Zeuzem S, Feinman SV, Rasenack J. (2000):** Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med*; 343(23):1666-72.
- **Zignego A.L., Ferri C., Caini P. and Bianchi F.B. (2006):** "For the Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C virus infection". *Dig. Liver Dis.*: p 23.
- **Zimmerman, Donald W. (1997):** "A Note on Interpretation of the Paired-Samples t Test". *Journal of Educational and Behavioral Statistics* 22 (3): 349–360.
- **Ziol M, Handra-luca A, Kettaneh A, Christidis C, et al.(2005):** Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology*; 2005;41:48-54.
- **Zobair M.; Younossi M.D. (2008):** New Directions in Hepatitis C Therapy. A Look at the Evolving Therapeutic Arsenal; From Mescape *Gastroenterology*, Hepatitis C Expert Column. Published: 09/05/2008.
- **Zuckerman E., Yeshurun D., Rosner I. (2001):** *Management of hepatitis C virus-related arthritis. Bio. Drugs* 2001; 15:573-84.